Literature DB >> 17696512

Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres.

G S Kiran Kumar Reddy1, Akbar Ali, Madhavi N L Nalam, Saima Ghafoor Anjum, Hong Cao, Robin S Nathans, Celia A Schiffer, Tariq M Rana.   

Abstract

A series of novel HIV-1 protease inhibitors based on two pseudosymmetric dipeptide isosteres have been synthesized and evaluated. The inhibitors were designed by incorporating N-phenyloxazolidinone-5-carboxamides into the hydroxyethylene and (hydroxyethyl)hydrazine dipeptide isosteres as P2 and P2' ligands. Compounds with (S)-phenyloxazolidinones attached at a position proximal to the central hydroxyl group showed low nM inhibitory activities against wild-type HIV-1 protease. Selected compounds were further evaluated for their inhibitory activities against a panel of multidrug-resistant protease variants and for their antiviral potencies in MT-4 cells. The crystal structures of lopinavir (LPV) and two new inhibitors containing phenyloxazolidinone-based ligands in complex with wild-type HIV-1 protease have been determined. A comparison of the inhibitor-protease structures with the LPV-protease structure provides valuable insight into the binding mode of the new inhibitors to the protease enzyme. Based on the crystal structures and knowledge of structure-activity relationships, new inhibitors can be designed with enhanced enzyme inhibitory and antiviral potencies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17696512      PMCID: PMC3862176          DOI: 10.1021/jm070284z

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  39 in total

1.  Synthesis, antiviral activity, and pharmacokinetic evaluation of P3 pyridylmethyl analogs of oximinoarylsulfonyl HIV-1 protease inhibitors.

Authors:  John T Randolph; Peggy P Huang; William J Flosi; David DeGoey; Larry L Klein; Clinton M Yeung; Charles Flentge; Mingua Sun; Chen Zhao; Tatyana Dekhtyar; Hongmei Mo; Lynn Colletti; Warren Kati; Kennan C Marsh; Akhteruzzaman Molla; Dale J Kempf
Journal:  Bioorg Med Chem       Date:  2006-02-28       Impact factor: 3.641

2.  Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.

Authors:  Arun K Ghosh; Perali Ramu Sridhar; Sofiya Leshchenko; Azhar K Hussain; Jianfeng Li; Andrey Yu Kovalevsky; D Eric Walters; Joseph E Wedekind; Valerie Grum-Tokars; Debananda Das; Yasuhiro Koh; Kenji Maeda; Hiroyuki Gatanaga; Irene T Weber; Hiroaki Mitsuya
Journal:  J Med Chem       Date:  2006-08-24       Impact factor: 7.446

3.  Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds.

Authors:  R Pauwels; J Balzarini; M Baba; R Snoeck; D Schols; P Herdewijn; J Desmyter; E De Clercq
Journal:  J Virol Methods       Date:  1988-08       Impact factor: 2.014

4.  Evaluation of methods for estimating the dissociation constant of tight binding enzyme inhibitors.

Authors:  W R Greco; M T Hakala
Journal:  J Biol Chem       Date:  1979-12-10       Impact factor: 5.157

5.  Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments.

Authors:  Thomas D Wu; Celia A Schiffer; Matthew J Gonzales; Jonathan Taylor; Rami Kantor; Sunwen Chou; Dennis Israelski; Andrew R Zolopa; W Jeffrey Fessel; Robert W Shafer
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

6.  Rational design of peptide-based HIV proteinase inhibitors.

Authors:  N A Roberts; J A Martin; D Kinchington; A V Broadhurst; J C Craig; I B Duncan; S A Galpin; B K Handa; J Kay; A Kröhn
Journal:  Science       Date:  1990-04-20       Impact factor: 47.728

7.  TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates.

Authors:  Sandra De Meyer; Hilde Azijn; Dominique Surleraux; Dirk Jochmans; Abdellah Tahri; Rudi Pauwels; Piet Wigerinck; Marie-Pierre de Béthune
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

8.  ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.

Authors:  D J Kempf; K C Marsh; J F Denissen; E McDonald; S Vasavanonda; C A Flentge; B E Green; L Fino; C H Park; X P Kong
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

9.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors.

Authors:  J H Condra; W A Schleif; O M Blahy; L J Gabryelski; D J Graham; J C Quintero; A Rhodes; H L Robbins; E Roth; M Shivaprakash
Journal:  Nature       Date:  1995-04-06       Impact factor: 49.962

10.  L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor.

Authors:  B D Dorsey; R B Levin; S L McDaniel; J P Vacca; J P Guare; P L Darke; J A Zugay; E A Emini; W A Schleif; J C Quintero
Journal:  J Med Chem       Date:  1994-10-14       Impact factor: 7.446

View more
  14 in total

Review 1.  Tetrahydrofuran, tetrahydropyran, triazoles and related heterocyclic derivatives as HIV protease inhibitors.

Authors:  Arun K Ghosh; David D Anderson
Journal:  Future Med Chem       Date:  2011-07       Impact factor: 3.808

2.  Crystallographic study of multi-drug resistant HIV-1 protease lopinavir complex: mechanism of drug recognition and resistance.

Authors:  Zhigang Liu; Ravikiran S Yedidi; Yong Wang; Tamaria G Dewdney; Samuel J Reiter; Joseph S Brunzelle; Iulia A Kovari; Ladislau C Kovari
Journal:  Biochem Biophys Res Commun       Date:  2013-06-18       Impact factor: 3.575

3.  Structure-based design, synthesis, and structure-activity relationship studies of HIV-1 protease inhibitors incorporating phenyloxazolidinones.

Authors:  Akbar Ali; G S Kiran Kumar Reddy; Madhavi N L Nalam; Saima Ghafoor Anjum; Hong Cao; Celia A Schiffer; Tariq M Rana
Journal:  J Med Chem       Date:  2010-11-11       Impact factor: 7.446

4.  New approaches to HIV protease inhibitor drug design II: testing the substrate envelope hypothesis to avoid drug resistance and discover robust inhibitors.

Authors:  Madhavi N L Nalam; Celia A Schiffer
Journal:  Curr Opin HIV AIDS       Date:  2008-11       Impact factor: 4.283

5.  Synthesis of a Chloroalkene Dipeptide Isostere-Containing Peptidomimetic and Its Biological Application.

Authors:  Takuya Kobayakawa; Yudai Matsuzaki; Kentaro Hozumi; Wataru Nomura; Motoyoshi Nomizu; Hirokazu Tamamura
Journal:  ACS Med Chem Lett       Date:  2017-12-27       Impact factor: 4.345

6.  Additivity in the analysis and design of HIV protease inhibitors.

Authors:  Robert N Jorissen; G S Kiran Kumar Reddy; Akbar Ali; Michael D Altman; Sripriya Chellappan; Saima G Anjum; Bruce Tidor; Celia A Schiffer; Tariq M Rana; Michael K Gilson
Journal:  J Med Chem       Date:  2009-02-12       Impact factor: 7.446

7.  Identification of novel HIV 1--protease inhibitors: application of ligand and structure based pharmacophore mapping and virtual screening.

Authors:  Divya Yadav; Sarvesh Paliwal; Rakesh Yadav; Mahima Pal; Anubhuti Pandey
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

8.  Multi-target QSAR modelling in the analysis and design of HIV-HCV co-inhibitors: an in-silico study.

Authors:  Qi Liu; Han Zhou; Lin Liu; Xi Chen; Ruixin Zhu; Zhiwei Cao
Journal:  BMC Bioinformatics       Date:  2011-07-20       Impact factor: 3.169

9.  Structural analyses of 2015-updated drug-resistant mutations in HIV-1 protease: an implication of protease inhibitor cross-resistance.

Authors:  Chinh Tran-To Su; Wei-Li Ling; Wai-Heng Lua; Yu-Xuan Haw; Samuel Ken-En Gan
Journal:  BMC Bioinformatics       Date:  2016-12-22       Impact factor: 3.169

10.  Heteroaromatic π-stacking energy landscapes.

Authors:  Roland G Huber; Michael A Margreiter; Julian E Fuchs; Susanne von Grafenstein; Christofer S Tautermann; Klaus R Liedl; Thomas Fox
Journal:  J Chem Inf Model       Date:  2014-05-09       Impact factor: 4.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.